^
    Back
    Association details:
    Biomarker:KRAS G12C
    Cancer:Lung Adenocarcinoma
    Drug:Krazati (adagrasib) (KRAS G12C inhibitor) +
    TVB-3664 (Fatty acid inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: D – Preclinical
    Source:
    Lung Cancer
    Title:

    Loss of wild type KRAS in KRAS MUT lung adenocarcinoma is associated with cancer mortality and confers sensitivity to FASN inhibitors

    Published date:
    01/02/2021
    Excerpt:
    ...we termed loss of heterozygosity (LOH) for any RAS (LAR) or LAKR in the context of KRAS (LOH at KRAS), is found in patients with RAS MUT cancers…FASN inhibitors such as TVB-3664 showed synergistic effects with the KRAS G12C inhibitor MRTX849 in LUAD cells with KRAS G12C and LAKR, including an in vivo trial using a xenograft model.
    DOI:
    10.1016/j.lungcan.2020.12.032